Soleno Therapeutics Inc
Soleno Therapeutics (ticker: SLNO) is a clinical-stage biotechnology company focused on developing treatments for rare endocrine and metabolic disorders. Investors should know it concentrates on a small number of specialised product candidates intended to address conditions with limited existing therapies. As a clinical-stage firm, valuation is closely tied to trial results, regulatory milestones and potential partnerships or licensing deals. The stock’s market capitalisation is approximately $3.57bn, reflecting investor expectations about future clinical and commercial progress. Typical investor considerations include high clinical and regulatory risk, potential for significant share-price volatility around news flow, and a longer time horizon for commercial returns if candidates are approved. This summary provides general educational information and is not personalised investment advice; prospective investors should carry out further research and consider their risk tolerance before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Soleno Therapeutics' stock with a target price of $113.54, indicating strong growth potential.
Financial Health
Soleno Therapeutics is performing well with strong revenue and cash flow, indicating financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SLNO
Beyond The Needle: The Oral GLP-1 Revolution
Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.
Published: August 28, 2025
Explore BasketOral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: August 27, 2025
Explore BasketThe Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
Published: August 15, 2025
Explore BasketExecutive Conviction In The GLP-1 Market
Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Published: August 13, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
Investors watch trial progress and regulatory milestones as primary value drivers, though outcomes are uncertain and can cause volatility.
Potential catalysts
Upcoming readouts, approvals or partnerships could materially affect valuation, but clinical and regulatory risks remain significant.
Niche market focus
Targeting rare endocrine disorders can mean high unmet need and pricing power if approved, balanced by small patient populations and commercial uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
